German September HICP Inflation Confirmed at 1.8% y/y

German September HICP Inflation Confirmed at 1.8% y/y

German September harmonized index of consumer prices inflation was confirmed at 1.8% y/y, unchanged from the preliminary number as well as the previous month. Energy price inflation picked up again, and excluding household energy and petrol, the annual rate dropped back to 1.7% y/y from 1.8% y/y. Still, the German inflation rate, like the Spanish, is pretty much in line with price stability now. And with the labor market looking […]

Read More ˃
ADMA Biologics Enters $40 Mln Interest-Only Credit Deal With Marathon Asset

ADMA Biologics Enters $40 Mln Interest-Only Credit Deal With Marathon Asset

ADMA Biologics (ADMA), a developer of plasma-based products to treat disease, Wednesday said it entered into a credit agreement for up to $40 million with Marathon Asset Management. ADMA said it will use proceeds to refinance its outstanding secured loan with Oxford Finance, and for working and growth capital. ADMA reported it received from Marathon $30 million of a senior secured term loan, with an additional $10 million senior secured […]

Read More ˃
Mustang Bio Says R&D Partner Gets $12.8 Mln Grant to Fund Phase 1 Brain Cancer Study

Mustang Bio Says R&D Partner Gets $12.8 Mln Grant to Fund Phase 1 Brain Cancer Study

Mustang Bio (MBIO), a Fortress Biotech (FBIO) company said Wednesday that research and development partner City of Hope has received a $12.8 million grant from the California Institute for Regenerative Medicine to fund an ongoing phase 1 study of Mustang’s cell-therapy MB-101 for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma. Mustang Bio said the funds will be used to expand the study and to explore […]

Read More ˃
Recro Pharma Unveils PDUFA Date for IV Meloxicam 30mg

Recro Pharma Unveils PDUFA Date for IV Meloxicam 30mg

Recro Pharma (REPH), a specialty pharmaceutical company, said Thursday the U.S. Food and Drug Administration has set a PDUFA date of May 26, 2018 for its decision on the New Drug Application (NDA) for for intravenous (IV) meloxicam 30mg for the management of moderate to severe pain. Meloxicam is a long-acting, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory and antipyretic activities, which are believed to be related to the inhibition […]

Read More ˃
Gold Seen at Vertical Research as Benefitting on Accommodative Monetary Policies

Gold Seen at Vertical Research as Benefitting on Accommodative Monetary Policies

Gold and shares of companies that mine the precious metal are expected to hold steady if not advance on the belief that central banks around the world will keep monetary accommodation in place, according to Vertical Research Partners, a Connecticut-based equity research and consulting firm focused on industrials and materials. “We believe metals in general and gold in particular should continue to gain traction as accommodative policy reversal appears pushed […]

Read More ˃